GeoVax (GOVX) stock is down around 11% in the last 5 days. Chairman and CEO, David Dodd, says that the clinical stage biotech company develops immunotherapies and vaccines against cancers and infectious diseases. GeoVax has Covid-19 trials for immunocompromised patients and a booster for MRNA treatment.
24 Nov 2021
Morning Trade Live
07 Nov 2022
Market On Close
23 Oct 2022
Morning Trade Live
14 Nov 2022
Market On Close
03 Oct 2022
The Watch List
21 Nov 2022
Market On Close
28 Sep 2022